| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
KRas G12D
Mutant KRAS G12D protein, specifically the Kras4B splice variant. This compound targets the G12D mutant form of KRAS, a key driver oncogene in many human cancers, including pancreatic, colorectal, and lung cancers. |
|---|---|
| ln Vitro |
In mouse embryonic fibroblasts (MEFs) harboring the Kras4B G12D mutation, Kras4B G12D-IN-1 effectively reduces Kras protein expression at the cellular level. This demonstrates its ability to engage its target and reduce the levels of this oncogenic driver.
|
| ln Vivo |
As an inhibitor of the Kras4B G12D mutant, this compound would be expected to have in vivo antitumor effects in models of KRAS G12D-driven cancers. By decreasing Kras protein expression, it likely impairs tumor cell proliferation and survival. However, specific in vivo tumor efficacy data is not reported.
|
| Enzyme Assay |
Not reported. A cell-free assay for this compound is not applicable, as its mechanism is to reduce Kras protein expression, which requires intact cellular machinery. It does not directly inhibit KRAS enzymatic activity or binding, making cell-free biochemical assays irrelevant for evaluating its function.
|
| Cell Assay |
For cellular efficacy, mouse embryonic fibroblasts (MEFs) engineered to express the Kras4B G12D mutant are seeded in 6-well plates. These cells are treated with varying concentrations of Kras4B G12D-IN-1 for 24-72 hours. Cells are then lysed, and KRAS protein levels are assessed by Western blot using a KRAS-specific antibody to quantify target reduction.
|
| Animal Protocol |
In vivo studies can be performed in mouse xenograft models using human cancer cell lines harboring the KRAS G12D mutation (e.g., PANC-1 for pancreatic cancer). Kras4B G12D-IN-1 is administered orally or intraperitoneally. Tumor volume is measured regularly with calipers, and at study termination, tumors are harvested for KRAS protein expression analysis by Western blot and IHC.
|
| ADME/Pharmacokinetics |
Not reported. The pharmacokinetic properties of Kras4B G12D-IN-1 have not been reported. As a small molecule with a molecular weight of 372.87, it may be orally bioavailable, but empirical data on its absorption, distribution, metabolism, and excretion are lacking.
|
| Toxicity/Toxicokinetics |
Not reported. No toxicology data is available. Its mechanism of reducing KRAS protein expression, rather than inhibiting mutant-specific activity, could potentially lead to on-target toxicities in normal tissues that depend on wild-type KRAS for proliferation and survival.
|
| References | |
| Additional Infomation |
Kras4B G12D-IN-1 is a research compound targeting the G12D mutant of KRAS, one of the most common and difficult-to-treat oncogenic drivers in pancreatic, colorectal, and non-small cell lung cancers. Unlike other approaches that target the GTP-bound active state or inhibit downstream effectors, this compound reduces total Kras protein expression, potentially offering a novel strategy for inhibiting KRAS-driven tumor growth. Further research is needed to validate its in vivo antitumor activity and therapeutic potential.
|
| Molecular Formula |
C16H21CLN2O4S
|
|---|---|
| Molecular Weight |
372.866942167282
|
| Exact Mass |
372.091
|
| CAS # |
2042365-85-3
|
| PubChem CID |
145184470
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
24
|
| Complexity |
549
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
COC1=C(C=C(C=C1)Cl)C(=O)N2CCC[C@@H](C2)CNS(=O)(=O)C=C
|
| InChi Key |
OUHXNDKRYIEFPD-GFCCVEGCSA-N
|
| InChi Code |
InChI=1S/C16H21ClN2O4S/c1-3-24(21,22)18-10-12-5-4-8-19(11-12)16(20)14-9-13(17)6-7-15(14)23-2/h3,6-7,9,12,18H,1,4-5,8,10-11H2,2H3/t12-/m1/s1
|
| Chemical Name |
N-[[(3S)-1-(5-chloro-2-methoxybenzoyl)piperidin-3-yl]methyl]ethenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6819 mL | 13.4095 mL | 26.8190 mL | |
| 5 mM | 0.5364 mL | 2.6819 mL | 5.3638 mL | |
| 10 mM | 0.2682 mL | 1.3409 mL | 2.6819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
